Myelofibrosis is a Secondary Event in JAK2 Trilinear Myeloproliferative Neoplasm (MPN) and in CALR and MPL Thrombocythemia: Implications for Novel Treatment Options of Prefibrotic MPN

Michiels JJ^1,3,4,5*, Berneman Z¹, Gadisseur A¹, Raeve HD², Schroyens W¹, Potter V³, Schelfout K³ and Valster F³

¹Department of Hematology, Antwerp University Hospital, Edegem, Belgium

²Department of Pathology, Antwerp University Hospital, OLVG Hospital Aalst and University of Brussels, Belgium

³Department of Pathology, Bravis Hospital, Bergen op Zoom, Netherlands

⁴Department of Internal Medicine and Hematology, Bravis Hospital, Bergen op Zoom, Netherlands

⁵Goodheart Institute and Foundation in Nature Medicine & Health, Rotterdam, Netherlands

^*Corresponding Author: Michiels JJ, Goodheart Institute and Foundation in Nature Medicine & Health, Freedom of Science and Education, Rotterdam, Netherlands, Tel: +316-26970534 Email: